QIAGEN N.V.: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
March 24, 2021 at 05:07 pm EDT
Share
DGAP Voting Rights Announcement: QIAGEN N.V.
QIAGEN N.V.: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
24.03.2021 / 22:06
Dissemination of a Voting Rights Announcement transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The AFM (the Netherlands Authority For the Financial Markets has informed us on March 20, 2021 that a notification related to our institution has been released by the AFM.
The following notification has been disclosed in the relevant register on the AFM website:
Date of transaction: 16 mar 2021
Person obliged to notify: Goldman Sachs Group Inc., The
Issuing institution: Qiagen N.V.
Registration Chamber of Commerce: 12036979
Place of residence: VENLO
Distribution in numbers
Type of share
Number of shares
Number of voting rights
Capital interest
Voting rights
Manner of disposal
Settlement
Contract for difference
75.351,00
75.351,00
Potential
Potential
Indirectly - Goldman Sachs International
In cash
Contract for difference
15.243,00
15.243,00
Potential
Potential
Indirectly - Goldman Sachs & Co. LLC
In cash
Swap
2.044,00
2.044,00
Potential
Potential
Indirectly - Goldman Sachs & Co. LLC
In cash
Swap
14.576,00
14.576,00
Potential
Potential
Indirectly - Goldman Sachs International
In cash
Ordinary share
2.500,00
2.500,00
Real
Real
Indirectly - United Capital Financial Advisers, LLC
Physical Delivery
Ordinary share
167.259,00
167.259,00
Real
Real
Indirectly - Goldman Sachs International
Physical Delivery
Ordinary share
868.650,00
868.650,00
Real
Real
Indirectly - Goldman Sachs Asset Management, L.P.
Physical Delivery
Convertible bond
568.374,00
568.374,00
Potential
Potential
Indirectly - Goldman Sachs International
Physical Delivery
Warrant
68.964,00
68.964,00
Potential
Potential
Indirectly - Goldman Sachs International
In cash
Option
3.863.782,00
3.863.782,00
Potential
Potential
Indirectly - Goldman Sachs & Co. LLC
Physical Delivery
Ordinary share
321.584,00
321.584,00
Potential
Potential
Indirectly - Goldman Sachs & Co. LLC
Physical Delivery
Ordinary share
4.262,00
4.262,00
Real
Real
Indirectly - Goldman Sachs Asset Management International
Physical Delivery
Ordinary share
823.397,00
823.397,00
Potential
Potential
Indirectly - Goldman Sachs International
Physical Delivery
Warrant
2.531,00
2.531,00
Potential
Potential
Indirectly - Goldman, Sachs & Co. Wertpapier GmbH
In cash
Swap
82.026,00
82.026,00
Potential
Potential
Indirectly - Goldman, Sachs & Co. Wertpapier GmbH
In cash
Ordinary share
36,00
36,00
Real
Real
Indirectly - Folio Investments Inc.
Physical Delivery
Distribution in percentages
Type
Total holding
Directly real
Directly potential
Indirectly real
Indirectly potential
Capital interest
2,98%
0,00%
0,00%
0,45%
2,53%
Voting rights
2,98%
0,00%
0,00%
0,45%
2,53%
QIAGEN N.V. is not responsible for the accuracy and correctness of the notification above. The content has been taken from the relevant register of the AFM: https://www.afm.nl/en/professionals/registers/meldingenregisters/substantiele-deelnemingen/details?id=108465
24.03.2021 The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de
Qiagen NV is a holding company based in the Netherlands. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials. Its assay technologies make these biomolecules visible for analysis, such as identifying the genetic information of a pathogen or a gene mutation in a tumor. Its bioinformatics solutions interpret data to provide actionable insights. The Company's automation platforms based on polymerase chain reaction (PCR), next-generation sequencing (NGS) and other technologies tie these together in molecular testing workflows from Sample to Insight.
QIAGEN N.V. 
